Response to meta-chlorophenylpiperazine in panic disorder patients and healthy subjects

Influence of reduction in intravenous dosage

Mark Germine, Andrew W. Goddard, Diane E. Sholomskas, Scott W. Woods, Dennis S. Charney, George R. Heninger

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

As a further test of the hypothesis of serotonin hypersensitivity in panic disorder (PD), the serotonin agonist meta-chlorophenylpiperazine (MCPP) was administered intravenously in a dose of 0.05 mg/kg to 27 PD patients and 22 normal control subjects. This is one-half the dose used in our previous study of PD patients, where the dose may have been too high to provide evidence of hypersensitivity to the agent. Responses of anxiety and nervousness were statistically indistinguishable by analysis of variance in the two groups, replicating our previous findings. Panic attack symptom score (PASS) ratings were significantly higher in the PD group, compared with a trend toward higher PASS ratings in the 0.1 mg/kg study. Cortisol, human growth hormone, and male prolactin responses showed no significant differences in the two groups by analysis of variance. Prolactin responses were significantly blunted in the female patients. The unexpected blunted prolactin response to MCPP in female PD patients may reflect a nonspecific blunting of prolactin response to stress. The PASS data provide some evidence of serotonergic hypersensitivity in PD.

Original languageEnglish (US)
Pages (from-to)115-133
Number of pages19
JournalPsychiatry Research
Volume54
Issue number2
DOIs
StatePublished - 1994
Externally publishedYes

Fingerprint

Panic Disorder
Healthy Volunteers
Prolactin
Hypersensitivity
Analysis of Variance
Anxiety
1-(3-chlorophenyl)piperazine
Serotonin Receptor Agonists
Human Growth Hormone
Hydrocortisone
Serotonin

Keywords

  • Anxiety
  • prolactin
  • serotonin
  • sex differences

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Psychology(all)

Cite this

Response to meta-chlorophenylpiperazine in panic disorder patients and healthy subjects : Influence of reduction in intravenous dosage. / Germine, Mark; Goddard, Andrew W.; Sholomskas, Diane E.; Woods, Scott W.; Charney, Dennis S.; Heninger, George R.

In: Psychiatry Research, Vol. 54, No. 2, 1994, p. 115-133.

Research output: Contribution to journalArticle

Germine, Mark ; Goddard, Andrew W. ; Sholomskas, Diane E. ; Woods, Scott W. ; Charney, Dennis S. ; Heninger, George R. / Response to meta-chlorophenylpiperazine in panic disorder patients and healthy subjects : Influence of reduction in intravenous dosage. In: Psychiatry Research. 1994 ; Vol. 54, No. 2. pp. 115-133.
@article{0ea507b8b6714f4f836642af2535c140,
title = "Response to meta-chlorophenylpiperazine in panic disorder patients and healthy subjects: Influence of reduction in intravenous dosage",
abstract = "As a further test of the hypothesis of serotonin hypersensitivity in panic disorder (PD), the serotonin agonist meta-chlorophenylpiperazine (MCPP) was administered intravenously in a dose of 0.05 mg/kg to 27 PD patients and 22 normal control subjects. This is one-half the dose used in our previous study of PD patients, where the dose may have been too high to provide evidence of hypersensitivity to the agent. Responses of anxiety and nervousness were statistically indistinguishable by analysis of variance in the two groups, replicating our previous findings. Panic attack symptom score (PASS) ratings were significantly higher in the PD group, compared with a trend toward higher PASS ratings in the 0.1 mg/kg study. Cortisol, human growth hormone, and male prolactin responses showed no significant differences in the two groups by analysis of variance. Prolactin responses were significantly blunted in the female patients. The unexpected blunted prolactin response to MCPP in female PD patients may reflect a nonspecific blunting of prolactin response to stress. The PASS data provide some evidence of serotonergic hypersensitivity in PD.",
keywords = "Anxiety, prolactin, serotonin, sex differences",
author = "Mark Germine and Goddard, {Andrew W.} and Sholomskas, {Diane E.} and Woods, {Scott W.} and Charney, {Dennis S.} and Heninger, {George R.}",
year = "1994",
doi = "10.1016/0165-1781(94)90001-9",
language = "English (US)",
volume = "54",
pages = "115--133",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Response to meta-chlorophenylpiperazine in panic disorder patients and healthy subjects

T2 - Influence of reduction in intravenous dosage

AU - Germine, Mark

AU - Goddard, Andrew W.

AU - Sholomskas, Diane E.

AU - Woods, Scott W.

AU - Charney, Dennis S.

AU - Heninger, George R.

PY - 1994

Y1 - 1994

N2 - As a further test of the hypothesis of serotonin hypersensitivity in panic disorder (PD), the serotonin agonist meta-chlorophenylpiperazine (MCPP) was administered intravenously in a dose of 0.05 mg/kg to 27 PD patients and 22 normal control subjects. This is one-half the dose used in our previous study of PD patients, where the dose may have been too high to provide evidence of hypersensitivity to the agent. Responses of anxiety and nervousness were statistically indistinguishable by analysis of variance in the two groups, replicating our previous findings. Panic attack symptom score (PASS) ratings were significantly higher in the PD group, compared with a trend toward higher PASS ratings in the 0.1 mg/kg study. Cortisol, human growth hormone, and male prolactin responses showed no significant differences in the two groups by analysis of variance. Prolactin responses were significantly blunted in the female patients. The unexpected blunted prolactin response to MCPP in female PD patients may reflect a nonspecific blunting of prolactin response to stress. The PASS data provide some evidence of serotonergic hypersensitivity in PD.

AB - As a further test of the hypothesis of serotonin hypersensitivity in panic disorder (PD), the serotonin agonist meta-chlorophenylpiperazine (MCPP) was administered intravenously in a dose of 0.05 mg/kg to 27 PD patients and 22 normal control subjects. This is one-half the dose used in our previous study of PD patients, where the dose may have been too high to provide evidence of hypersensitivity to the agent. Responses of anxiety and nervousness were statistically indistinguishable by analysis of variance in the two groups, replicating our previous findings. Panic attack symptom score (PASS) ratings were significantly higher in the PD group, compared with a trend toward higher PASS ratings in the 0.1 mg/kg study. Cortisol, human growth hormone, and male prolactin responses showed no significant differences in the two groups by analysis of variance. Prolactin responses were significantly blunted in the female patients. The unexpected blunted prolactin response to MCPP in female PD patients may reflect a nonspecific blunting of prolactin response to stress. The PASS data provide some evidence of serotonergic hypersensitivity in PD.

KW - Anxiety

KW - prolactin

KW - serotonin

KW - sex differences

UR - http://www.scopus.com/inward/record.url?scp=0028670086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028670086&partnerID=8YFLogxK

U2 - 10.1016/0165-1781(94)90001-9

DO - 10.1016/0165-1781(94)90001-9

M3 - Article

VL - 54

SP - 115

EP - 133

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 2

ER -